JC

James Calloway

Financial Reporter

James Calloway is a financial reporter at StockTi covering corporate earnings, regulatory policy, and market-moving events. A former business journalist with Reuters, James has covered financial markets for over eight years across New York and Washington. He specializes in breaking down earnings reports, SEC filings, and policy decisions that affect publicly traded companies and investor portfolios.

Earnings, Regulation 460 articles

Articles by James Calloway

Amazon Shares Drop 5.6% on $200 Billion AI Spending Forecast
Earnings

Amazon Shares Drop 5.6% on $200 Billion AI Spending Forecast

Amazon stock declined sharply after projecting a major increase in capital expenditures for 2026, even as broader markets reached new highs. Investors are scrutinizing the returns from massive tech investments in artificial intelligence.

AMZN NVDA MSFT GOOGL
Home Depot Shares Edge Higher Ahead of Key Economic Data, Q4 Earnings
Earnings

Home Depot Shares Edge Higher Ahead of Key Economic Data, Q4 Earnings

Home Depot stock gained 0.7% Friday as investors await delayed jobs and inflation reports. The home improvement retailer's Q4 earnings, due Feb. 24, will test demand in a cautious housing market.

HD
AbbVie Shares Gain 2% to Close Near $223 Amid Earnings Volatility, Credit Upgrade
Earnings

AbbVie Shares Gain 2% to Close Near $223 Amid Earnings Volatility, Credit Upgrade

AbbVie stock rose 2% Friday, ending a turbulent week marked by earnings scrutiny and a Moody's credit rating upgrade. Investors remain focused on Skyrizi and Rinvoq growth amid competitive pressures.

ABT JNJ
FDA Crackdown on Compounded Weight-Loss Drugs Boosts Eli Lilly Shares
Regulation

FDA Crackdown on Compounded Weight-Loss Drugs Boosts Eli Lilly Shares

Eli Lilly stock gained 3.7% after FDA signaled action against telehealth firm Hims & Hers over $49 compounded weight-loss alternatives. Regulatory uncertainty continues to impact obesity drug market valuations.

LLY